| Literature DB >> 35417721 |
Zachary D Stolp1, Madhura Kulkarni1, Yining Liu1, Chengzhang Zhu1, Alizay Jalisi2, Si Lin1, Arturo Casadevall1, Kyle W Cunningham3, Fernando J Pineda4, Xinchen Teng5, J Marie Hardwick6.
Abstract
Unicellular eukaryotes have been suggested as undergoing self-inflicted destruction. However, molecular details are sparse compared with the mechanisms of programmed/regulated cell death known for human cells and animal models. Here, we report a molecular cell death pathway in Saccharomyces cerevisiae leading to vacuole/lysosome membrane permeabilization. Following a transient cell death stimulus, yeast cells die slowly over several hours, consistent with an ongoing molecular dying process. A genome-wide screen for death-promoting factors identified all subunits of the AP-3 complex, a vesicle trafficking adapter known to transport and install newly synthesized proteins on the vacuole/lysosome membrane. To promote cell death, AP-3 requires its Arf1-GTPase-dependent vesicle trafficking function and the kinase Yck3, which is selectively transported to the vacuole membrane by AP-3. Video microscopy revealed a sequence of events where vacuole permeability precedes the loss of plasma membrane integrity. AP-3-dependent death appears to be conserved in the human pathogenic yeast Cryptococcus neoformans.Entities:
Keywords: AP-3; CP: Cell biology; Yck3; cryptococcus; lysosome; programmed cell death; regulated cell death; vacuolar membrane permeabilization; vacuole; vesicle trafficking; yeast
Mesh:
Substances:
Year: 2022 PMID: 35417721 PMCID: PMC9074372 DOI: 10.1016/j.celrep.2022.110647
Source DB: PubMed Journal: Cell Rep Impact factor: 9.995
Figure 1.Protracted time to death following heat-ramp stress
(A) Temperature plot for the 18 min, 30°C–51°C heat-ramp cell death stimulus delivered to log phase yeast throughout this study, except where noted (Teng et al., 2011).
(B) Cell death of wild-type yeast (BY4709) after heat-ramp determined as percent of starting cell number by propidium iodide (PI) or phloxine B (Phlox) staining in liquid phase (≤2 h post-heat-ramp) or in solid phase to avoid counting progeny of survivors (≥24 h), and by visible colony forming units (cfus, 48 h only). Mean ± SD plotted for 3–4 independent experiments per condition, counting ~200 per sample. Two-tailed t test, *p = 0.0157, **p = 0.0122, and two-way ANOVA with Tukey’s honest significant difference (HSD); p = 0.1006 to compare all three assays at 48 h.
(C) Time to death (phloxine+) determined by video microscopy of ~300 cells per strain after heat-ramp determined in solid phase. Median time to death (dashed line); range (blue box) for five wild-type strains under these growth and media conditions.
(D) Video microscopy frames from an independent time-lapse experiment, as described in (C). Example cells dying 9–16 h post-heat-ramp (white arrows) and early or delayed proliferation/clonogenicity (yellow arrows). Scale bar, 25 μm.
(E) Mother (lower larger) or daughter (upper smaller) cells may die first (phloxine+, arrows).
Figure 2.Genome-wide screen identifies death-resistant AP-3 deletion strains
(A) Rank ordered survival of yeast knockout strains (BY4741) from genome-wide screen after post-diauxic-phase 20 min, 30°–62°C linear heat-ramp. Initial hit cutoff set at 1.5× interquartile range above 75th percentile of Z scores, ~2.47.
(B) Gene ontology component enrichment analysis of the 84 screen hits compared with all strains analyzed with Bonferroni correction for multiple hypothesis testing.
(C) Low throughput cell death assay of log phase optical density 600 (OD600)-adjusted cultures (BY4741) spotted on plates pre- and post-heat-ramp.
(D) Quantification for (C) from 3 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, *p ≤ 0.0048.
(E and F) As described for (C) and (D), except for SEY6210 background strains from 3 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, *p ≤ 0.0043.
(G) Survival (cfus) of newly generated CRISPR knockouts of APM3 in the amino acid prototroph BY4709. Quantified for 3 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, *p = 0.0068. Genome sequence and trafficking function tests in Figures S1A–S1D.
(H) As in (G), for new CRISPR knockout of APS3 (BY4709). Quantified for 6 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, *p = 1.24 × 10−8. Genome sequence and trafficking function tests in Figures S1E–S1H.
(I) As in (H), for new APS3 knockout generated by conventional recombination (BY4742). Quantified for 6 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, *p = 2.4 × 10−8.
Figure 3.Rescue of AP-3 restores cell death induced by multiple stimuli
(A) Impending death of wild-type and Δaps3 in liquid cultures assessed as percent phloxine-positive before and ~15 min after heat-ramp. N = 3 independent experiments per condition, two-way ANOVA with Tukey’s HSD test post hoc, *p = 4.77 × 10−7.
(B) Same samples in (A) stained with propidium iodide (PI), *p = 1.54 × 10−4.
(C) Images from video microscopy of phloxine-stained wild-type (WT) and Δaps3 after heat-ramp. Scale bars, 25 μm.
(D) Quantification for (C) from 3 independent experiments; time to death (50%) for Δaps3 estimated by linear regression. One-way ANOVA with repeated measures, *p = 1.5 × 10−7.
(E) Rescue of Δaps3 cell death by C-terminal flag-tagged (fl) APS3 and native promoter. Viability determined by cfus on selection medium before and after heat-ramp (or acetic acid or H2O2, Figure S3).
(F) Quantification for (E), N = 3 independent experiments, two-way ANOVA with Tukey’s HSD test post hoc for Δaps3 + Aps3-flag rescue versus Δaps3 (*p = 1.78 × 10−7) or Δaps3 + control vector (*p = 1.53 × 10−7), respectively. WT versus Δaps3 (p = 1.95 × 10−7) or Δaps3 + control vector (p = 2.29 × 10−7). Western blot of unheated samples with anti-ALP/Pho8, anti-flag, and anti-PGK loading control.
(G) Summary of tetrad analysis for sporulated heterozygous diploids of WT crossed to Δapl5 (all 42 validated tetrads tested) and Δaps3 (all 6 validated tetrads tested). Death resistance uniformly segregated 2:2 with KanMX knockout marker.
(H) Resistance of new CRISPR Δaps3 strain to 242 mM acetic acid. N = 3 independent experiments, two-way ANOVA with Tukey’s HSD test post hoc, *p = 0.0064, **p = 0.0043.
(I) Resistance of new Δaps3 to 50 mM H2O2-induced death. N = 6 biological replicates from 3 independent experiments, two-way ANOVA with Tukey’s HSD test post hoc, *p = 0.0014, **p = 7.95 × 10−6.
(J) Resistance of new CRISPR knockout (KO) Δapm3 to 50 mM H2O2-induced death. N = 6 biological replicates from 3 independent experiments, two-way ANOVA with Tukey’s HSD test post hoc, *p = 3.25 × 10−5.
Figure 4.AP-3 promotes cell death via its canonical vesicle trafficking functions
(A) Alignment of AP-3 orthologues, yeast Alp6, human AP-1 (AP1β), and human AP-3 (AP3β); conserved Arf1-binding contact sites (boxed).
(B) Fluorescent microscopy of GFP-Sna2 localization in yeast stained with FM4–64 (red) to mark vacuole membranes, and cell wall stain UVITEX (blue) to approximate the plasma membrane. Scale bar, 5 μm.
(C) Immunoblot of endogenous alkaline phosphatase (ALP/Pho8) to detect AP-3/vacuole-dependent processing of the precursor to proteolytically matured and soluble forms.
(D) Quantification for (C), calculated as Pho8 precursor relative to total (precursor + mature + soluble) for 3 independent experiments after pooling results for 2–3 independent strains per genotype. Two-way ANOVA with Tukey’s HSD test post hoc, *p = 1.56 × 10−6, **p = 3.23 × 10−5, ***p = 1.57E-10.
(E) Viability of sequence-verified APL6-modified yeast strains (Figure S4) following heat-ramp and spotted on agar plates.
(F) Quantification for (E), plotted as log10 (cfus/mL) for 3 independent experiments after pooling results for 2–3 independent strains per genotype. Two-way ANOVA with Tukey’s HSD test post hoc, *p = 2.67 × 10−6, **p = 3.98 × 10−12, ***p = 1.06 × 10−12.
Figure 5.AP-3 is required shortly before the cell death stimulus
(A) Viability of yeast pre-treated 4 h with either solvent control (ethanol) or 50 μM auxin (IAA) to degrade Apl5-AID-6xflag prior to heat-ramp and plated on agar in 3-fold serial dilutions.
(B) Quantification for (A); 6 independent experiments plotted as [(log10 cfus/mL with auxin) − (log10 cfus/mL with ethanol)]. Two-way ANOVA with Tukey’s HSD test post hoc: APL5 versus APL5-AID (*p = 6.81 × 10−7); Δapl5 versus APL5-AID (*p = 2.2 × 10−7); and Δapl5 versus APL5 (p = 0.931, ns).
(C) Immunoblots (upper) of yeast with anti-flag to monitor degradation of Apl5-TAP-AID-6xflag during 0–4 h with solvent control (ethanol) or 50 μM auxin (IAA). Immunoblot (lower) with anti-ALP/Pho8 to monitor AP-3 trafficking function based on maturation status of Pho8. *Non-specific band.
(D) Quantified AP-3 function for (C), calculated from densitometry as amount of precursor protein relative to total ALP/Pho8, and relative ALP defect is plotted as auxin/ethanol versus untreated for 4 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, ****p = 9.5 × 10−4, ***p = 5.7 × 10−4, **p = 0.00201, *p = 2.09 × 10−5, ns = 0.128.
(E) Relative survival of WT yeast pre-incubated with solvent alone or 50 μM auxin (IAA) prior to heat-ramp at time = 0, calculated as [(log10 cfus/mL with auxin or ethanol) − (log10 cfus/mL untreated)] for 5 independent experiments. Two-way ANOVA with Tukey’s HSD test post hoc, *p = 0.0016, **p = 5.2 × 10−9, ***p = <1.0 × 10−13.
(F) Heat-ramp cell death assay for three single-cell-derived substrains (BY4741) corresponding to AP-3 cargo proteins Yck3 and Atg27, and other cargo proteins (Figure S5).
(G) Heat-ramp cell death assay and corresponding genotypes verified by NAT or KAN (G418) drug selectivity for four spore-derived strains from a tetratype tetrad produced by sporulating heterozygous diploids (Δaps3:NatMx6 × Δyck3:KanMx4) and summary of death resistance scores for 32 spore-derived strains tested (8 tetrads).
(H) Fluorescent microscopy of WT and Δaps3 pre-stained with CMAC and imaged before and 30 min after heat-ramp. Arrowheads mark examples of heat-treated cells with retained vacuolar CMAC, quantified as percent of cells. Two-tailed t test for 3 fields from one experiment, counting >1,500 cells per genotype, *p = 0.0063.
Figure 6.AP-3-dependent vacuole membrane permeabilization
(A) Video microscopy images of wild-type yeast pre-stained with CMAC and imaged in phloxine at the indicated time stamps after heat-ramp. CMAC is presented as pixel intensity heatmap (color key, right), gray scale, and green fluorescence. Arrows mark spots where CMAC first emerges from the vacuole (depicted in Figure 6Fiii); arrowheads mark earliest phloxine staining. Scale bar, 2.5 μm.
(B) WT yeast expressing Pep4-Envy pre-stained with CMAC and imaged in phloxine ~20 min after heat-ramp. Dashed circles surround perimeter of example live (phlox−) cells that retain CMAC in the vacuole (Figure 6Fi and ii); arrowheads: example live (phlox−) cell with cytoplasmic CMAC but vacuolar Pep4 (Figure 6Fiii); white arrows: example live (phlox−) cells with partial or complete release of both CMAC and Pep4-Envy (Figure 6Fiii and iv); blue arrows: dying/dead cells (phlox+) with released Pep4 and fading/released CMAC (Figure 6Fv); and yellow arrows: dead cells (high phlox+) with released Pep4 and loss of CMAC (Figure 6Fvi). Scale bar, 5 μm.
(C) Quantification for (D) two-way ANOVA with Tukey’s HSD test post hoc for 3 fields from one experiment, counting >300 cells per genotype, *p = 0.0035, **p = 0.012, ***p = 1.05 × 10−5.
(D) WT and Δaps3 pre-stained with CMAC and imaged in phloxine before or ~30 min after heat-ramp. Dashed circles: surrounds perimeter of live (phlox−) cells with retained CMAC (Figure 6Fi and ii); white arrows: live (phlox−) cells with released CMAC (Figure 6Fiii and iv); and blue arrows: dead/dying (low or high phlox+) and released CMAC. Scale bar, 5 μm.
(E) WT yeast expressing Vph1-Envy pre-stained with CMAC and imaged in phloxine ~30 min after heat-ramp. Dashed circle: surrounds live (phlox−) cell with vacuolar CMAC (Figure 6Fii); white arrows: live (phlox−) with released CMAC and retained vacuole organelle structure (Vph1-Envy) (Figure 6Fv); and orange arrows: dying/dead cells (low phlox+) with released CMAC and indistinct vacuole membranes (Figure 6Fvi). Bright phlox+ cells depicted in Figure 6Fvii. Brightness of phloxine images in (B–E) was increased 20%. Scale bar, 5 μm.
(F) Diagram of the observed sequence of events described in (B–E).
Figure 7.Cryptococcus neoformans AP-3 deficiency enhances survival
(A) Heat-ramp cell death assay adapted for Cryptococcus neoformans, comparing wild type and knockout of AP-3 subunit Apl5 homolog (CNAG_02468).
(B) Quantification for (A), boxplot of pooled results from 2 independent experiments testing the knockout for CNAG_02468 and two single-colony-derived knockout substrains normalized to wild-type KN99 control. Paired, two-tailed t test comparing log2 (cfu/mL) WT versus log2 (cfu/mL) ΔC.n. apl5 for heat-treated samples, *p = 0.0024; untreated samples are not different, p = 0.599.
(C) Proposed yeast AP-3 vesicle trafficking cell death pathway depicts Arf1-dependent docking of AP-3 complex (based on PDB: 6DFF) at late/post-Golgi membranes (based on Video S3, in Levi et al., 2010); AP-3 recognition of Tyr motif in membrane-anchored casein kinase Yck3, which phosphorylates other proteins to promote vesicle fusion, vacuole membrane permeabilization, and cell death.
(D) Order of events and potential commitment points in the AP-3 cell death pathway.
KEY RESOURCES TABLE
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| Mouse monoclonal anti-FLAG M2 (1:5000) | Sigma-Aldrich | Cat# F3165; RRID:AB_259529 |
| Mouse monoclonal anti-PGK 22C5D8 (1:5000) | Abcam | Abcam Cat# ab197960; RRID:AB_2756444 |
| Purified rabbit polyclonal anti-Pho8 (anti-CPY) (1:1000) | Gregory Payne; ( | N/A |
| Purified rabbit polyclonal anti-Apm3 (1:5000) | Sandra Lemmon; ( | N/A |
| Sheep anti-mouse HRP secondary (1:5000) | GE Healthcare | Cat# NA931; RRID:AB_772210 |
| Donkey anti-rabbit HRP secondary (1:5000) | GE Healthcare | Cat# NA934; RRID:AB_772206 |
| Chemicals, peptides, and recombinant proteins | ||
| CMAC (7-amino-4-chloromethycoumarin) | ThermoFisher Scientific | Cat#C2110 |
| Nourseothricin sulfate (NAT) | GoldBio | Cat#N500; CAS RN#96736-11-7 |
| Phloxine B | FisherScientific | Cat#P387-25 |
| Propidium Iodide | Invitrogen | Cat#P3566 |
| FM4-64 ( | ThermoFisher Scientific | Cat#T13320 |
| UVITEX 2B | Fisher Scientific (Polysciences, Inc.) | Cat#NC9859220 |
| IAA (3-indoleacetic acid) | Millipore Sigma | Cat#I3750 |
| Sabouraud dextrose (SAB) medium | BD Difco | BD238230; Cat#DF0382-17-9 |
| Deposited data | ||
| Uncropped western blots for all figures | Mendeley Data |
|
| Experimental models: Organisms/strains | ||
| BY4709 [ | J. Boeke; ( | N/A ( |
| BY4741 [ | J. Boeke; ( | N/A ( |
| BY4742 [ | J. Boeke; ( | N/A ( |
| BY4741-JMH [ | This paper | N/A ( |
| BY4741 Δ | J. Boeke; ( | N/A ( |
| BY4741 Δ | ( | N/A ( |
| BY4741 Δ | J. Boeke; ( | N/A ( |
| BY4741 Δ | J. Boeke; ( | N/A ( |
| BY4741 Δ | J. Boeke; ( | N/A ( |
| BY4741 Δ | J. Boeke; ( | N/A ( |
| BY4741 Δ | J. Boeke; ( | N/A ( |
| SEY6210 ( | SusanMichaelis; ( | N/A |
| SEY6210 (CCY254 Δ | Scott Emr ( | N/A ( |
| SEY6210 (GOY4 Δ | Scott Emr ( | N/A ( |
| SEY6210 (GOY3 Δ | Scott Emr ( | N/A ( |
| SEY6210 (GOY5 Δ | Scott Emr ( | N/A ( |
| W303a [ | Susan Michaelis, Johns Hopkins University | N/A ( |
| ZSY200 (BY4742 Δ | This paper | N/A ( |
| ZSY201 (BY4709 pCRCT control colony #1 (D1) for APS3/APM3 CRISPR strains) | This paper | N/A ( |
| ZSY202 (BY4709 pCRCT control colony #2 (E1) for APS3/APM3 CRISPR strains) | This paper | N/A ( |
| ZSY203 (BY4709 Δaps3 CRISPR colony #1 (D2); sequence confirmed) | This paper | N/A ( |
| ZSY204 (BY4709 Δaps3 CRISPR colony #2 (E2); sequence confirmed) | This paper | N/A ( |
| ZSY205 (BY4709 Δaps3 CRISPR colony #3 (F2); sequence confirmed) | This paper | N/A ( |
| ZSY206 (BY4709 Δapm3 CRISPR colony #1 (D4); sequenced as WT) | This paper | N/A ( |
| ZSY207 (BY4709 Δapm3 CRISPR colony #2 (E4); sequenced as WT) | This paper | N/A ( |
| ZSY208 (Δapm3 CRISPR colony #3 (F2); sequence confirmed) | This paper | N/A ( |
| ZSY243 (ZSY200 + pRS303) [Δ | This paper | N/A ( |
| ZSY248 (ZSY200 + APS3-flag) [Δ | This paper | N/A |
| ZSY209 (BY4709 pCRCT control colony #1 (B8) for APL6 CRISPR strains; sequence confirmed) | This paper | N/A ( |
| ZSY210 (BY4709 pCRCT control colony #2, B9, for APL6 CRISPR strains; sequence confirmed) | This paper | N/A ( |
| ZSY211 (BY4709 Δapl6 CRISPR colony #1 (C8); sequence confirmed) | This paper | N/A ( |
| ZSY212 (BY4709 Δapl6 CRISPR colony #2 (C9); sequence confirmed) | This paper | N/A ( |
| ZSY213 (BY4709 Δapl6 CRISPR colony #3 (C10); sequence confirmed) | This paper | N/A ( |
| ZSY214 (BY4709 apl6L117D/I120D CRISPR colony #1, D8; sequence confirmed) | This paper | N/A ( |
| ZSY215 (BY4709 apl6L117D/I120D CRISPR colony #2, D9; sequence confirmed) | This paper | N/A ( |
| ZSY216 (BY4709 apl6L117D/I120D CRISPR colony #3, D10; sequence confirmed) | This paper | N/A ( |
| ZSY217(Δ | This paper | N/A ( |
| ZSY218 (Δ | This paper | N/A ( |
| ZSY219 WT [spore-derived from ZSY200 × Δ | This paper | N/A ( |
| ZSY220 (Δ | This paper | N/A ( |
| APL5-TAP (BY4741 | ( | N/A ( |
| APL5-AID ( | Kyle Cunningham; ( | N/A |
| ZSY223 (BY4741 | This paper | N/A ( |
| ZSY221 (BY4741 | This paper | N/A ( |
| FGSC 2016 Madhani plates, NIH R01AI100272 | ||
| FGSC 2016 Madhani plates, NIH R01AI100272 | ||
| Oligonucleotides | ||
| Sequences of Primers and CRISPR gene blocks are in | This paper | N/A |
| Recombinant DNA | ||
| Plasmid: p41Nat 1-F GW | Leonid Kruglyak, UCLA (unpublished) | Addgene #58546 |
| Plasmid: pCRCT (encodes iCas9 + tracrRNA) | ( | Addgene #60621 |
| Plasmid: pCRCT-APL6 disruption | This paper | N/A |
| Plasmid: pCRCT-APL6 L117D/I120D | This paper | N/A |
| Plasmid: pCRCT-APM3 disruption | This paper | N/A |
| Plasmid: pCRCT-APS3 disruption | This paper | N/A |
| Plasmid: pFA6A-link-GFPEnvy-SpHis5 | Linda Huang ( | Addgene #60782 |
| Plasmid: pRS303 | Susan Michaelis, Johns Hopkins University |
|
| Plasmid: pZDS100 (pRS303 + | This paper | N/A |
| Plasmid: pRS416 + | Pierre Morsomme; ( | N/A |
| Other | ||
| Preprint of earlier version of this manuscript | BioRxiv |
|